Current Report Filing (8-k)
May 25 2016 - 4:24PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
May 19, 2016
Date of report (date of earliest event
reported)
MusclePharm Corporation
(Exact name of registrant as specified
in its charter)
Nevada
|
|
000-53166
|
|
77-0664193
|
(State or other jurisdictions of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification Nos.)
|
4721 Ironton Street, Building A
Denver, Colorado 80239
(Address of principal
executive offices) (Zip Code)
(303) 396-6100
(Registrant’s telephone number,
including area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrants under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 1.02.
|
Termination of a Material Definitive Agreement.
|
On May 19, 2016, MusclePharm Corporation (the “Company”)
entered into a Settlement Agreement with ETW Corp. (the “Settlement Agreement”). The Settlement Agreement eliminates
all costs and terminates all future commitments between Tiger Woods and the Company under the Endorsement Agreement between the
Company and ETW, dated July 1, 2014 (as amended, the “Endorsement Agreement”).
The material terms of the Endorsement Agreement were previously
described in a Current Report on Form 8-K filed by the Company with the U.S. Securities and Exchange Commission on June 18, 2014,
which description is incorporated herein by reference.
Pursuant to the Settlement Agreement, the Company agreed to
pay $2.5 million to terminate the parties’ obligations under Endorsement Agreement, effective as of May 19, 2016, and to
resolve all disputes between them. As of March 31, 2016, the Company had accrued $7.0 million in relation to the Endorsement Agreement.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
MUSCLEPHARM CORPORATION
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ John Price
|
|
|
|
|
Name:
|
John Price
|
|
|
|
|
Title:
|
Chief Financial Officer
|
|
Date: May 25, 2016
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From Apr 2023 to Apr 2024